Johnson & Johnson Begins The Final Stage Of COVID-19 Vaccine Testing
On Wednesday, the American company Johnson & Johnson announced the transition to the third and final stage of testing the COVID-19 vaccine. Sixty thousand people will take part in these clinical trials. J&J started working on the vaccine in January, and the company started clinical trials in July.
J&J is now the fourth company after Moderna, Pfizer, and AstraZeneca to start the third phase of testing in the US. The difference between the vaccine she developed and the other three is that one dose of the vaccine is needed for vaccination, not two. The results of the current tests should be ready by the beginning of 2021. J&J, like other companies, has already agreed with the US authorities to supply them with 100 million doses of the COVID-19 vaccine for a total of $1 billion.
Last week, Moderna, Pfizer, and AstraZeneca released detailed information about their vaccine trials. This rejection of traditional secrecy in the development of vaccines and medicines is associated with pressure from the scientific community and the public at large.
These results have been submitted to medRxiv and are due to be published online imminently. Based on these results and following discussions with the U.S. Food and Drug Administration (FDA), ENSEMBLE will enroll up to 60,000 volunteers across three continents and will study the safety and efficacy of a single vaccine dose versus placebo in preventing COVID-19.